GlassScriptPhysician profile
Benjamin Scott Fontenot
NPI 1508283813
$8,293.11
in general payments reported to CMS, 2019-2025
43 companies · $586 in 2025
The $586 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,487 · 2020: $992 · 2021: $1,261 · 2022: $1,490 · 2023: $1,423 · 2024: $1,054 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,978 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,977.87 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,502.41 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $783.56 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $780.84 | 2021-2025 | |
| Amgen INC. | $767.68 | 2019-2025 | Repatha, Otezla, Prolia |
| Glaxosmithkline, LLC. | $734.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $484.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.30 | 2019-2023 | Jardiance, Synjardy |
| Abbott Laboratories | $355.55 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $243.29 | 2019-2023 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $224.81 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $196.84 | 2019-2022 | |
| Antares Pharma, INC. | $180.90 | 2019-2025 | Xyosted |
| Teva Pharmaceuticals USA, INC. | $164.74 | 2019-2021 | |
| Pfizer INC. | $148.26 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $143.99 | 2022-2024 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Fontenot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.